Factors associated with overall survival in 68 patients with mastocytosis treated by 2-CdA
| Covariates . | HR . | 95% CI . | P . |
|---|---|---|---|
| Male gender | 3.69 | 1.42-9.54 | .007 |
| AHNMD vs ISM/SSM/CM/MIS | 11.56 | 2.49-53.63 | .001* |
| ASM vs ISM/SSM/CM/MIS | 15.43 | 3.34-71.18 | .001* |
| Age at mastocytosis diagnosis >50 y | 7.26 | 2.41-21.88 | .001* |
| Age at 2-CdA initiation >55 y | 5.67 | 1.90-16.9 | .02 |
| Fatigue | 4.89 | 0.65-36.5 | .12 |
| Flush | 0.41 | 0.17-0.99 | .049 |
| Pruritus | 0.35 | 0.13-0.9 | .029 |
| Abdominal pain | 1.22 | 0.51-2.89 | .65 |
| Diarrhea | 0.82 | 0.34-1.96 | .66 |
| Hepatosplenomegaly | 16.45 | 2.2-122.9 | .006 |
| Urticaria pigmentosa | 0.16 | 0.07-0.39 | .0005 |
| Bone involvement | 1.52 | 0.64-3.61 | .35 |
| Anemia | 4.43 | 1.80-10.9 | .001 |
| Covariates . | HR . | 95% CI . | P . |
|---|---|---|---|
| Male gender | 3.69 | 1.42-9.54 | .007 |
| AHNMD vs ISM/SSM/CM/MIS | 11.56 | 2.49-53.63 | .001* |
| ASM vs ISM/SSM/CM/MIS | 15.43 | 3.34-71.18 | .001* |
| Age at mastocytosis diagnosis >50 y | 7.26 | 2.41-21.88 | .001* |
| Age at 2-CdA initiation >55 y | 5.67 | 1.90-16.9 | .02 |
| Fatigue | 4.89 | 0.65-36.5 | .12 |
| Flush | 0.41 | 0.17-0.99 | .049 |
| Pruritus | 0.35 | 0.13-0.9 | .029 |
| Abdominal pain | 1.22 | 0.51-2.89 | .65 |
| Diarrhea | 0.82 | 0.34-1.96 | .66 |
| Hepatosplenomegaly | 16.45 | 2.2-122.9 | .006 |
| Urticaria pigmentosa | 0.16 | 0.07-0.39 | .0005 |
| Bone involvement | 1.52 | 0.64-3.61 | .35 |
| Anemia | 4.43 | 1.80-10.9 | .001 |
AHNMD, associated hematological non–mast cell disease; ASM, aggressive systemic mastocytosis; CM, cutaneous mastocytosis; ISM, indolent systemic mastocytosis; MIS, mastocytosis in the skin; SSM, smoldering systemic mastocytosis.
Bold indicates significant parameters in univariate analysis.
Significant parameters after multivariate analysis.